Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03399513
Title Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma (R-CHOEP-brut)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital Muenster
Indications

diffuse large B-cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Etoposide + Ibrutinib + Prednisolone + Rituximab + Vincristine Sulfate

Age Groups: adult
Covered Countries DEU

Facility Status City State Zip Country Details
HELIOS Hospital Berlin-Buch Berlin 13125 Germany Details
Hospital Chemnitz Chemnitz 09116 Germany Details
University Hospital Cologne Cologne 50937 Germany Details
University Hospital Göttingen Göttingen 37075 Germany Details
University Hospital Hamburg-Eppendorf Hamburg 20246 Germany Details
University Hospital Heidelberg Heidelberg 69120 Germany Details
Saarland University Hospital Homburg 66421 Germany Details
Johannes Wesling Hospital Minden Minden 32429 Germany Details
University Hospital Muenster Muenster 48149 Germany Details
Rostock University Medical Center Rostock 18057 Germany Details
University Hospital Tuebingen Tuebingen 72076 Germany Details
University Hospital Ulm Ulm 89081 Germany Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field